Chemins
This article was originally published in The Tan Sheet
Executive Summary
July sentencing scheduled for dietary supplement manufacturer and its founder and president, who pleaded guilty Jan. 6 to charges of conspiring to hide use of ephedrine hydrochloride and caffeine anhydrous from the FDA. In exchange for the plea, the U.S. Attorney agrees to dismiss the remaining counts of the indictment, including product misbranding; making false statements; aiding and abetting; and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in supplements. Chemins and exec James Cameron originally entered not guilty pleas in Denver federal court Nov. 9 (1"The Tan Sheet" Nov. 15, 1999, In Brief)
You may also be interested in...
Chemins
Dietary supplement manufacturer and its founder and president entered not guilty pleas in Denver federal court Nov. 9 to charges of product misbranding, conspiracy, making false statements, aiding and abetting, and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in its products. No trial date has been set. A grand jury on Oct. 21 returned a 14-count indictment against the company and exec James Cameron related to the manufacture of Formula One supplements with ma huang and kola nut (1"The Tan Sheet" Oct. 25, p. 5)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands